Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 16, 2007

Medarex and Organon Ink Biotherapeutics Development Agreement

  • Organon, the human health care business unit of Akzo Nobel, and Medarex will work together to develop and potentially commercialize fully human antibody therapeutics for the treatment of cancer and auto-immune disorders, utilizing Medarex’s UltiMAb Human Antibody Development System® and Organon’s expertise in drug discovery and development.

    Under the terms of the agreement, Medarex and Organon plan to share development and commercialization responsibilities on any antibody-based therapeutics resulting from this collaboration and to share revenues generated from the sale of such therapeutic products.

    “We have recently increased our efforts in Cambridge, Massachusetts, to identify novel biologicals that will be effective treatments for auto-immune and oncological disorders, this additional collaboration with Medarex represents a further step toward becoming an effective biological drug hunting company,” says David Nicholson, executive vp, R&D, at Organon.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »